| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
254,921 |
421,551 |
1,262,027 |
1,480,093 |
| Total Sell Value |
$16,747,919 |
$26,516,522 |
$74,515,877 |
$82,888,946 |
| Total People Sold |
8 |
9 |
12 |
12 |
| Total Sell Transactions |
23 |
40 |
87 |
90 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Raynor Daniel |
Director |
– • – |
2018-03-14 |
4 |
S |
$62.02 |
$119,016 |
I/I |
(1,919) |
296,218 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2018-03-14 |
4 |
S |
$62.03 |
$620,300 |
D/D |
(10,000) |
185,706 |
|
- |
|
| Raynor Daniel |
Director |
– • – |
2018-03-13 |
4 |
S |
$61.81 |
$1,123,023 |
I/I |
(18,117) |
298,137 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2018-03-13 |
4 |
S |
$61.52 |
$1,852,843 |
D/D |
(30,000) |
195,706 |
|
- |
|
| Raynor Daniel |
Director |
– • – |
2018-03-12 |
4 |
S |
$62.88 |
$498,513 |
I/I |
(7,928) |
316,254 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2018-03-12 |
4 |
OE |
$6.36 |
$99,998 |
D/D |
15,723 |
225,706 |
|
- |
|
| Marshbanks Tracy |
Director |
– • – |
2018-03-12 |
4 |
S |
$63.03 |
$773,315 |
I/I |
(12,269) |
485,713 |
|
- |
|
| Marshbanks Tracy |
Director |
– • – |
2018-03-09 |
4 |
S |
$63.01 |
$2,303,709 |
I/I |
(36,561) |
497,982 |
|
- |
|
| Marshbanks Tracy |
Director |
– • – |
2018-03-08 |
4 |
S |
$63.08 |
$970,864 |
I/I |
(15,391) |
534,543 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2018-03-05 |
4 |
S |
$61.92 |
$258,640 |
D/D |
(4,177) |
65,470 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2018-03-05 |
4 |
OE |
$6.36 |
$199,947 |
D/D |
18,001 |
69,647 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2018-03-01 |
4 |
S |
$60.33 |
$1,766,771 |
D/D |
(28,652) |
12,938 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2018-03-01 |
4 |
OE |
$28.76 |
$539,250 |
D/D |
18,750 |
41,590 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2018-03-01 |
4 |
S |
$60.59 |
$1,468,695 |
D/D |
(23,986) |
209,983 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2018-03-01 |
4 |
OE |
$6.36 |
$643,287 |
D/D |
23,986 |
233,969 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2017-05-22 |
4 |
D |
$47.01 |
$46,587 |
D/D |
(991) |
210,833 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2017-05-22 |
4 |
D |
$47.01 |
$21,155 |
D/D |
(450) |
22,840 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2017-05-22 |
4 |
D |
$47.01 |
$13,069 |
D/D |
(278) |
51,549 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2017-04-17 |
4 |
D |
$51.22 |
$13,829 |
D/D |
(270) |
23,290 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2017-04-17 |
4 |
D |
$51.22 |
$59,466 |
D/D |
(1,161) |
211,824 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2017-04-07 |
4 |
D |
$51.24 |
$21,879 |
D/D |
(427) |
23,560 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2017-04-07 |
4 |
D |
$51.24 |
$74,349 |
D/D |
(1,451) |
212,985 |
|
- |
|
| Carey Stephen P. |
Vice President and CFO |
• – – |
2017-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
6,625 |
6,625 |
|
- |
|
| Raynor Daniel |
Director |
– • – |
2017-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
11,110 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2017-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
23,750 |
214,436 |
|
- |
|
722 Records found
|
|
Page 14 of 29 |
|
|
0.14 (0.21%) 
